Unicycive Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Unicycive Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Unicycive Therapeutics Inc
Rating: 1.25083325
Author: Trendlyne DVM scores

about

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed ...

4.62 0.00 (0.00%)

58.00% Fall from 52W High

354.4K

XNAS Volume

XNAS 03 Oct, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

4.3 / 100

Technically Neutral

45.7 / 100

1Yr Price target upside is 35%

6 analysts

Unicycive Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Unicycive Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed ...

58.00% Fall from 52W High

SWOT Analysis

Unicycive Therapeutics Inc Live Price Chart